US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
IL73534A
(en)
|
1983-11-18 |
1990-12-23 |
Riker Laboratories Inc |
1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
US4754065A
(en)
|
1984-12-18 |
1988-06-28 |
Cetus Corporation |
Precursor to nucleic acid probe
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
US4800159A
(en)
|
1986-02-07 |
1989-01-24 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
US5047335A
(en)
|
1988-12-21 |
1991-09-10 |
The Regents Of The University Of Calif. |
Process for controlling intracellular glycosylation of proteins
|
US5756747A
(en)
|
1989-02-27 |
1998-05-26 |
Riker Laboratories, Inc. |
1H-imidazo 4,5-c!quinolin-4-amines
|
US4929624A
(en)
|
1989-03-23 |
1990-05-29 |
Minnesota Mining And Manufacturing Company |
Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
US5389640A
(en)
|
1991-03-01 |
1995-02-14 |
Minnesota Mining And Manufacturing Company |
1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
US5278299A
(en)
|
1991-03-18 |
1994-01-11 |
Scripps Clinic And Research Foundation |
Method and composition for synthesizing sialylated glycosyl compounds
|
CA2103059C
(en)
|
1991-06-14 |
2005-03-22 |
Paul J. Carter |
Method for making humanized antibodies
|
US5268376A
(en)
|
1991-09-04 |
1993-12-07 |
Minnesota Mining And Manufacturing Company |
1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
US5266575A
(en)
|
1991-11-06 |
1993-11-30 |
Minnesota Mining And Manufacturing Company |
2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
|
AU3144193A
(en)
|
1991-11-21 |
1993-06-15 |
Board Of Trustees Of The Leland Stanford Junior University |
Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
|
DK1136556T3
(da)
|
1991-11-25 |
2005-10-03 |
Enzon Inc |
Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
|
ATE149570T1
(de)
|
1992-08-17 |
1997-03-15 |
Genentech Inc |
Bispezifische immunoadhesine
|
KR100341341B1
(ko)
|
1993-07-15 |
2002-11-25 |
미네소타 마이닝 앤드 매뉴팩춰링 캄파니 |
이미다조[4,5-c]피리딘-4-아민
|
US5352784A
(en)
|
1993-07-15 |
1994-10-04 |
Minnesota Mining And Manufacturing Company |
Fused cycloalkylimidazopyridines
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US6239116B1
(en)
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
WO1996002555A1
(en)
|
1994-07-15 |
1996-02-01 |
The University Of Iowa Research Foundation |
Immunomodulatory oligonucleotides
|
US5482936A
(en)
|
1995-01-12 |
1996-01-09 |
Minnesota Mining And Manufacturing Company |
Imidazo[4,5-C]quinoline amines
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
AU698419B2
(en)
|
1996-07-03 |
1998-10-29 |
Dainippon Sumitomo Pharma Co., Ltd. |
A novel purine derivative
|
US6387938B1
(en)
|
1996-07-05 |
2002-05-14 |
Mochida Pharmaceutical Co., Ltd. |
Benzimidazole derivatives
|
JP4101302B2
(ja)
|
1997-01-09 |
2008-06-18 |
テルモ株式会社 |
新規アミド誘導体および合成中間体
|
US6406705B1
(en)
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
US6426334B1
(en)
|
1997-04-30 |
2002-07-30 |
Hybridon, Inc. |
Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
|
US6303347B1
(en)
|
1997-05-08 |
2001-10-16 |
Corixa Corporation |
Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
|
US6113918A
(en)
|
1997-05-08 |
2000-09-05 |
Ribi Immunochem Research, Inc. |
Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
|
ATE370740T1
(de)
|
1997-05-20 |
2007-09-15 |
Ottawa Health Research Inst |
Verfahren zur herstellung von nukleinsäurekonstrukten
|
WO1999028321A1
(fr)
|
1997-11-28 |
1999-06-10 |
Sumitomo Pharmaceuticals Company, Limited |
Nouveaux composes heterocycliques
|
UA67760C2
(uk)
|
1997-12-11 |
2004-07-15 |
Міннесота Майнінг Енд Мануфакчурінг Компані |
Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
|
TW572758B
(en)
|
1997-12-22 |
2004-01-21 |
Sumitomo Pharma |
Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
US6110929A
(en)
|
1998-07-28 |
2000-08-29 |
3M Innovative Properties Company |
Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
|
JP2000119271A
(ja)
|
1998-08-12 |
2000-04-25 |
Hokuriku Seiyaku Co Ltd |
1h―イミダゾピリジン誘導体
|
CA2376634A1
(en)
|
1999-06-08 |
2000-12-14 |
Aventis Pasteur |
Immunostimulant oligonucleotide
|
US6451810B1
(en)
|
1999-06-10 |
2002-09-17 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
US6573273B1
(en)
|
1999-06-10 |
2003-06-03 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
US6756382B2
(en)
|
1999-06-10 |
2004-06-29 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
US6331539B1
(en)
|
1999-06-10 |
2001-12-18 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
US6541485B1
(en)
|
1999-06-10 |
2003-04-01 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
CA2381993A1
(en)
|
1999-08-13 |
2001-02-22 |
Hybridon, Inc. |
Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
|
US6376669B1
(en)
|
1999-11-05 |
2002-04-23 |
3M Innovative Properties Company |
Dye labeled imidazoquinoline compounds
|
AU2001245823A1
(en)
|
2000-03-17 |
2001-10-03 |
Corixa Corporation |
Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
|
US6651132B1
(en)
|
2000-07-17 |
2003-11-18 |
Microsoft Corporation |
System and method for emulating the operation of a translation look-aside buffer
|
US6664264B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US6664260B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Heterocyclic ether substituted imidazoquinolines
|
US6677347B2
(en)
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamido ether substituted imidazoquinolines
|
US6545016B1
(en)
|
2000-12-08 |
2003-04-08 |
3M Innovative Properties Company |
Amide substituted imidazopyridines
|
US6664265B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
US6667312B2
(en)
|
2000-12-08 |
2003-12-23 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US6660747B2
(en)
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
US6660735B2
(en)
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Urea substituted imidazoquinoline ethers
|
US6525064B1
(en)
|
2000-12-08 |
2003-02-25 |
3M Innovative Properties Company |
Sulfonamido substituted imidazopyridines
|
UA74852C2
(en)
|
2000-12-08 |
2006-02-15 |
3M Innovative Properties Co |
Urea-substituted imidazoquinoline ethers
|
US6545017B1
(en)
|
2000-12-08 |
2003-04-08 |
3M Innovative Properties Company |
Urea substituted imidazopyridines
|
US6677348B2
(en)
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Aryl ether substituted imidazoquinolines
|
CN1604795B
(zh)
|
2001-08-17 |
2010-05-26 |
科勒制药股份公司 |
具有提高的活性的组合基序免疫刺激寡肽
|
AU2002365412B2
(en)
|
2001-11-27 |
2008-10-09 |
Anadys Pharmaceuticals, Inc. |
3-Beta-D-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof
|
US6677349B1
(en)
|
2001-12-21 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
US6525028B1
(en)
|
2002-02-04 |
2003-02-25 |
Corixa Corporation |
Immunoeffector compounds
|
EP1513524A4
(en)
|
2002-06-07 |
2008-09-03 |
3M Innovative Properties Co |
WITH ETHER SUBSTITUTED IMIDAZOPYRIDINE
|
DK1545597T3
(da)
|
2002-08-15 |
2011-01-31 |
3M Innovative Properties Co |
Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
|
AR040996A1
(es)
|
2002-08-19 |
2005-04-27 |
Coley Pharm Group Inc |
Acidos nucleicos inmunoestimuladores
|
JP2006503068A
(ja)
|
2002-09-26 |
2006-01-26 |
スリーエム イノベイティブ プロパティズ カンパニー |
1h−イミダゾダイマー
|
KR20050107497A
(ko)
|
2003-03-07 |
2005-11-11 |
쓰리엠 이노베이티브 프로퍼티즈 컴파니 |
1-아미노 1h-이미다조퀴놀린
|
EP2258365B1
(en)
|
2003-03-28 |
2013-05-29 |
Novartis Vaccines and Diagnostics, Inc. |
Use of organic compounds for immunopotentiation
|
MXPA06001674A
(es)
|
2003-08-12 |
2006-05-12 |
3M Innovative Properties Co |
Compuestos que contienen imidazo hidroxilamina-sustituidos.
|
EP1658076B1
(en)
|
2003-08-27 |
2013-03-06 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted imidazoquinolines
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
US7544697B2
(en)
|
2003-10-03 |
2009-06-09 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and analogs thereof
|
CA2540598C
(en)
|
2003-10-03 |
2013-09-24 |
3M Innovative Properties Company |
Pyrazolopyridines and analogs thereof
|
AU2004278014B2
(en)
|
2003-10-03 |
2011-04-28 |
3M Innovative Properties Company |
Alkoxy substituted imidazoquinolines
|
CN1906192A
(zh)
|
2003-11-14 |
2007-01-31 |
3M创新有限公司 |
羟胺取代的咪唑环化合物
|
EP1685129A4
(en)
|
2003-11-14 |
2008-10-22 |
3M Innovative Properties Co |
OXIMSUBSTITUTED IMIDAZORING CONNECTIONS
|
CA2547085A1
(en)
|
2003-11-25 |
2005-06-09 |
3M Innovative Properties Company |
Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
AR046781A1
(es)
|
2003-11-25 |
2005-12-21 |
3M Innovative Properties Co |
Derivados de imidazoquinolinas. composiciones farmaceuticas.
|
CN1914203A
(zh)
|
2003-12-04 |
2007-02-14 |
3M创新有限公司 |
砜取代的咪唑环醚
|
WO2005066172A1
(en)
|
2003-12-29 |
2005-07-21 |
3M Innovative Properties Company |
Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
|
WO2005066170A1
(en)
|
2003-12-29 |
2005-07-21 |
3M Innovative Properties Company |
Arylalkenyl and arylalkynyl substituted imidazoquinolines
|
CA2551399A1
(en)
|
2003-12-30 |
2005-07-21 |
3M Innovative Properties Company |
Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
|
WO2005094531A2
(en)
|
2004-03-24 |
2005-10-13 |
3M Innovative Properties Company |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
US20080015184A1
(en)
|
2004-06-14 |
2008-01-17 |
3M Innovative Properties Company |
Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
|
WO2005123080A2
(en)
|
2004-06-15 |
2005-12-29 |
3M Innovative Properties Company |
Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
US7884207B2
(en)
|
2004-06-18 |
2011-02-08 |
3M Innovative Properties Company |
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
US20070259881A1
(en)
|
2004-06-18 |
2007-11-08 |
Dellaria Joseph F Jr |
Substituted Imidazo Ring Systems and Methods
|
WO2006065280A2
(en)
|
2004-06-18 |
2006-06-22 |
3M Innovative Properties Company |
Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
|
WO2006038923A2
(en)
|
2004-06-18 |
2006-04-13 |
3M Innovative Properties Company |
Aryl substituted imidazonaphthyridines
|
US20070259907A1
(en)
|
2004-06-18 |
2007-11-08 |
Prince Ryan B |
Aryl and arylalkylenyl substituted thiazoloquinolines and thiazolonaphthyridines
|
WO2006009826A1
(en)
|
2004-06-18 |
2006-01-26 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
|
US20090270443A1
(en)
|
2004-09-02 |
2009-10-29 |
Doris Stoermer |
1-amino imidazo-containing compounds and methods
|
PL1789042T3
(pl)
|
2004-09-02 |
2012-09-28 |
3M Innovative Properties Co |
Układy pierścieni 1-alkoksy 1H-imidazo i sposoby
|
WO2006029115A2
(en)
|
2004-09-02 |
2006-03-16 |
3M Innovative Properties Company |
2-amino 1h imidazo ring systems and methods
|
WO2006028451A1
(en)
|
2004-09-03 |
2006-03-16 |
3M Innovative Properties Company |
1-amino 1-h-imidazoquinolines
|
EP1831221B1
(en)
|
2004-12-30 |
2012-08-08 |
3M Innovative Properties Company |
Substituted chiral fused 1,2 imidazo 4,5-c ring compounds
|
AU2005322898B2
(en)
|
2004-12-30 |
2011-11-24 |
3M Innovative Properties Company |
Chiral fused (1,2)imidazo(4,5-c) ring compounds
|
CA2597324C
(en)
|
2005-02-09 |
2015-06-30 |
Coley Pharmaceutical Group, Inc. |
Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
|
US8093390B2
(en)
|
2005-02-11 |
2012-01-10 |
3M Innovative Properties Company |
Substituted fused [1,2]imidazo[4,5-C] ring compounds and methods
|
CA2597446A1
(en)
|
2005-02-11 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Substituted imidazoquinolines and imidazonaphthyridines
|
AU2006213746A1
(en)
|
2005-02-11 |
2006-08-17 |
Coley Pharmaceutical Group, Inc. |
Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods
|
US8178677B2
(en)
|
2005-02-23 |
2012-05-15 |
3M Innovative Properties Company |
Hydroxyalkyl substituted imidazoquinolines
|
WO2006091647A2
(en)
|
2005-02-23 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Method of preferentially inducing the biosynthesis of interferon
|
EP1851220A2
(en)
|
2005-02-23 |
2007-11-07 |
3M Innovative Properties Company |
Hydroxyalkyl substituted imidazonaphthyridines
|
WO2006091567A2
(en)
|
2005-02-23 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Hydroxyalkyl substituted imidazoquinoline compounds and methods
|
EP1868650B1
(en)
|
2005-04-15 |
2018-10-03 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US9963510B2
(en)
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
WO2007147901A1
(en)
|
2006-06-22 |
2007-12-27 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
EP2591787A1
(en)
|
2007-08-13 |
2013-05-15 |
Pfizer Inc |
Combination motif immune stimulatory oligonucleotides with improved activity
|
EP2851374B1
(en)
|
2007-12-14 |
2017-05-03 |
Bristol-Myers Squibb Company |
Binding molecules to the human OX40 receptor
|
DK2235064T3
(en)
|
2008-01-07 |
2016-01-11 |
Amgen Inc |
A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
|
PT3056514T
(pt)
|
2008-01-15 |
2019-07-19 |
Univ Leland Stanford Junior |
Métodos para manipulação de fagocitose mediada por cd47
|
EP2111869A1
(en)
|
2008-04-23 |
2009-10-28 |
Stichting Sanquin Bloedvoorziening |
Compositions and methods to enhance the immune system
|
WO2010032060A1
(en)
*
|
2008-09-19 |
2010-03-25 |
Medimmune Llc |
Antibodies directed to dll4 and uses thereof
|
US8552165B2
(en)
|
2008-12-09 |
2013-10-08 |
Heather Davis |
Immunostimulatory oligonucleotides
|
EP2569337A1
(en)
|
2010-05-14 |
2013-03-20 |
Rinat Neuroscience Corp. |
Heterodimeric proteins and methods for producing and purifying them
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
BR112014012609A2
(pt)
|
2011-11-17 |
2020-10-20 |
Pfizer Inc |
peptídeos citotóxicos e conjungados de droga de anticorpo dos mesmos
|
US20140140989A1
(en)
|
2012-02-06 |
2014-05-22 |
Inhibrx Llc |
Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
|
CA2892585C
(en)
|
2012-12-03 |
2022-07-05 |
Novimmune S.A. |
Anti-cd47 antibodies and methods of use thereof
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
DK2970493T3
(da)
|
2013-03-15 |
2019-05-13 |
Univ Leland Stanford Junior |
Fremgangsmåder til opnåelse af terapeutisk effektive doser af anti-cd47-midler
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
JP2017520575A
(ja)
|
2014-07-01 |
2017-07-27 |
ファイザー・インク |
二重特異的ヘテロ二量体ダイアボディおよびその使用
|
US9501570B2
(en)
|
2014-07-14 |
2016-11-22 |
Verizon Patent And Licensing Inc. |
Dynamic routing system
|
BR112017007379A2
(pt)
|
2014-10-14 |
2017-12-19 |
Dana Farber Cancer Inst Inc |
moléculas de anticorpo para pd-l1 e usos das mesmas
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
US9719791B2
(en)
|
2014-12-10 |
2017-08-01 |
Mapquest, Inc. |
Computerized systems and methods for providing travel information and/or content to users
|
PT3656443T
(pt)
|
2015-01-21 |
2021-12-27 |
Univ Leland Stanford Junior |
Utilização de agonista trl e agente anti-cd47 para melhorar a fagocitose das células cancerígenas
|
DK3283106T3
(da)
|
2015-04-13 |
2022-01-10 |
Pfizer |
Terapeutiske antistoffer og anvendelser deraf
|
US10894831B2
(en)
|
2015-08-26 |
2021-01-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist
|
UA126146C2
(uk)
|
2015-09-18 |
2022-08-25 |
Арч Онколоджі, Інк. |
Терапевтичне антитіло до cd47
|
ES2796378T3
(es)
|
2016-01-11 |
2020-11-26 |
Forty Seven Inc |
Anticuerpos monoclonales anti-cd47 humanizados, de ratón o químicos
|
JP7026047B2
(ja)
|
2016-01-21 |
2022-02-25 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
免疫調節剤を併用するがんの治療
|
EP3995139A1
(en)
|
2016-04-10 |
2022-05-11 |
Georgia State University Research Foundation, Inc. |
Composition for use in treating cancer
|
CN115350276A
(zh)
|
2016-04-15 |
2022-11-18 |
小利兰·斯坦福大学托管委员会 |
用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法
|
US20200255515A1
(en)
|
2016-05-09 |
2020-08-13 |
Celgene Corporation |
Cd47 antibodies and methods of use thereof
|
CR20190062A
(es)
|
2016-08-15 |
2019-05-22 |
Pfizer |
Inhibidores de cdk2/4/6
|
EP3529276A4
(en)
|
2016-10-21 |
2020-06-17 |
Arch Oncology, Inc. |
CD47 THERAPEUTIC ANTIBODIES
|
JP7117311B2
(ja)
|
2017-01-26 |
2022-08-12 |
ゼットリップ ホールディング リミテッド |
Cd47抗原結合単位およびその使用
|
EP3592387A4
(en)
|
2017-03-09 |
2021-03-31 |
The Board of Trustees of the Leland Stanford Junior University |
TREATMENT OF PEDIATRIC BRAIN TUMORS WITH TARGETING THE CD47 SIGNAL PATH
|
CN111148535A
(zh)
|
2017-03-22 |
2020-05-12 |
安驰肿瘤公司 |
治疗实体癌和血液癌的组合疗法
|
CN110958888A
(zh)
|
2017-03-28 |
2020-04-03 |
延龄草治疗公司 |
Cd47阻断疗法
|
TWI816673B
(zh)
*
|
2017-05-08 |
2023-10-01 |
大陸商上海津曼特生物科技有限公司 |
雙特異性重組蛋白及其應用
|
AU2018272311A1
(en)
*
|
2017-05-26 |
2019-12-19 |
Novimmune Sa |
Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
|
AU2018277838A1
(en)
|
2017-05-31 |
2019-12-19 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
|
PE20191846A1
(es)
|
2017-06-02 |
2019-12-31 |
Pfizer |
Anticuerpos especificos para flt3 y sus usos
|
CN111356477A
(zh)
*
|
2017-08-01 |
2020-06-30 |
Ab工作室有限公司 |
双特异性抗体及其用途
|
EA039662B1
(ru)
|
2017-10-03 |
2022-02-24 |
Закрытое Акционерное Общество "Биокад" |
Антитела, специфичные к cd47 и pd-l1
|
EP4177270A1
(en)
|
2017-10-18 |
2023-05-10 |
Forty Seven, Inc. |
Anti-cd47 agent-based ovarian cancer therapy
|
EP4194470A1
(en)
|
2017-10-18 |
2023-06-14 |
Forty Seven, Inc. |
Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
|
US20200354458A1
(en)
|
2017-11-20 |
2020-11-12 |
Taizhou Mabtech Pharmaceutical Co., Ltd. |
Bifunctional Fusion Protein Targeting CD47 and PD-L1
|
CN111615521A
(zh)
|
2017-12-04 |
2020-09-01 |
北京韩美药品有限公司 |
抗pd-l1/抗cd47天然抗体结构样异源二聚体形式双特异抗体及其制备
|
US20210070855A1
(en)
|
2018-01-24 |
2021-03-11 |
Nanjing Legend Biotech Co., Ltd. |
Anti-cd47 antibodies that do not cause significant red blood cell agllutination
|
MX2020008184A
(es)
|
2018-02-01 |
2020-09-22 |
Pfizer |
Receptores de antigeno quimericos dirigidos a cd70.
|
WO2019166650A1
(en)
|
2018-03-02 |
2019-09-06 |
Cdr-Life Ag |
Trispecific antigen binding proteins
|
WO2019179434A1
(en)
|
2018-03-20 |
2019-09-26 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Novel bispecific pd-1/cd47 antibody molecules
|
KR20210029158A
(ko)
*
|
2018-06-03 |
2021-03-15 |
람카프 바이오 베타 엘티디. |
Ceacam5 및 cd47에 대한 이중특이성 항체
|
CN112739384A
(zh)
|
2018-09-04 |
2021-04-30 |
延龄草治疗公司 |
用于疾病治疗的cd47阻断和parp抑制
|
EP3860609A4
(en)
|
2018-10-01 |
2022-08-03 |
Secura Bio, Inc. |
COMBINATION THERAPIES
|
WO2020128893A1
(en)
|
2018-12-21 |
2020-06-25 |
Pfizer Inc. |
Combination treatments of cancer comprising a tlr agonist
|
AU2020205100A1
(en)
|
2019-01-04 |
2021-08-19 |
Trio Pharmaceuticals, Inc. |
Multi-specific protein molecules and uses thereof
|
WO2020198370A2
(en)
|
2019-03-25 |
2020-10-01 |
Arch Oncology, Inc. |
Therapeutic cd47 antibodies
|
CA3144244A1
(en)
|
2019-06-25 |
2020-12-30 |
Innovent Biologics (Suzhou) Co., Ltd. |
Formulation comprising anti-cd47/pd-l1 bispecific antibody, method for preparing same and use thereof
|